Gregory Tsai, MD
Otolaryngology · New York, NYNPI 1760484661
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,048 of the $1,218 with a category attached, or 86.0%. Intersect ENT, Inc. accounts for 60.2% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2019 at $792 and has fallen 77.0% since, to $182 in 2023. That places this record below the midpoint for otolaryngology clinicians in NY, where the typical reported total is $1,040.
Across 10 payments — averaging $121.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intersect ENT, Inc.$733
- Neurent Medical Limited$394
- Medtronic$32
- Olympus America Inc.$22
- Sanofi-aventis U.S. LLC$21
- Jazz Pharmaceuticals Inc.$15
What the payments were for
- Travel & lodging$17014%
- Food & beverage$1,04886%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intersect ENT, Inc. | 3 | $733 |
| Neurent Medical Limited | 2 | $394 |
| Medtronic | 2 | $32 |
| Olympus America Inc. | 1 | $22 |
| Sanofi-aventis U.S. LLC | 1 | $21 |
| Jazz Pharmaceuticals Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,218 in reported general payments places this provider in the 50th percentile of 701 otolaryngology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XywavSodium,calcium,mag,pot Oxybate | 12 | $244,190 |
| Ipratropium Bromide | 109 | $3,386 |
| Azelastine Hcl | 44 | $1,032 |
| Fluticasone Propionate | 61 | $604 |
| Fluocinolone Acetonide Oil | 26 | $524 |
| Famotidine | 82 | $397 |
| Omeprazole | 48 | $244 |
| Methylprednisolone | 19 | $160 |
| Prednisone | 11 | $23 |
Paid to pharmacies, not to this prescriber.
Other otolaryngology in New York
- Roheen RaithathaNew York$830K
- Dennis KrausNew York$159K
- Anthony DelsignoreNew York$89K
- Satish GovindarajNew York$39K
- Lawrence LustigNew York$33K
- Justin GolubNew York$30K
- Brett MilesNew York$30K
- David HiltzikNew York$25K
- Milan AminNew York$23K
- Ashutosh KackerNew York$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.